STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #919 by analyst upside · 2026-06-27
SLDB
Solid Biosciences Inc.
Healthcare · Market Cap $915M · P/E 0x
ANALYST PRICE TARGET
+87.1%
implied upside to consensus target
Current Price $9.29
Consensus Target $17.38
Bull Target $26.0
Bear Target $11.0
Analysts Covering 13
ANALYST CONSENSUS — BUY
Strong Buy
4
Buy
9
Hold
0
Sell
0
52-Week Low $3.79
52-Week High $9.78
YTD Return +70.5%
FUNDAMENTALS
Market Cap $915M
P/E Ratio (TTM) N/A
Forward P/E -4.7x
EPS (TTM) $-1.92
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.79
52-Week High $9.78
Current Price $9.29
Bear Target $11.0
Bull Target $26.0
● Now $9.29 ● Target $17.38
TRADING DATA
Avg Volume 1.5M
YTD Return +70.5%
Analyst Count 13
Consensus Buy
Upside to Target +87.1%
Last Updated 2026-06-27

ANALYST SUMMARY

Solid Biosciences Inc. (SLDB) is currently trading at $9.29 with a Wall Street consensus price target of $17.38, implying potential upside of 87.1% over the next 12 months. 13 analysts currently cover SLDB, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $26.0, while the most cautious has a target of $11.0.

SLDB operates in the Healthcare sector with a market capitalisation of $915M. The stock is up 70.5% year-to-date and is currently trading near the upper end of its 52-week range of $3.79 – $9.78.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SLDB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. — Reiterated
Buy → Buy 2026-06-03 31% win rate (48 calls)
Wedbush reit
Outperform → Outperform 2026-05-18 Building track record
Wedbush — Reiterated
Outperform → Outperform 2026-05-13 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2026-05-13 14% win rate (7 calls)
JP Morgan — Reiterated
Overweight → Overweight 2026-03-25 43% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-23 31% win rate (48 calls)
Guggenheim ● Initiated
Buy 2026-03-20 62% win rate (8 calls)
Chardan Capital — Reiterated
Buy → Buy 2026-03-20 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →